

May 30, 2025

To Shareholders,

Company Name: Renascience Inc.
Representative: Keisuke Furuta, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice of termination of joint research agreement with Daiichi Sankyo Co., Ltd. regarding novel coronavirus pneumonia and other lung injuries.

We have been discussing the future of the joint research agreement for novel coronavirus pneumonia and other lung injuries, etc., that we concluded with Daiichi Sankyo Co., Ltd. (disclosed in the "Notice of the conclusion of a joint research agreement with Kyoto University and Daiichi Sankyo Co., Ltd." on June 5, 2023), which expires on March 31, 2025. However, as the novel coronavirus pneumonia situation has subsided, we have decided to terminate the joint research agreement. At the same time, the preferred negotiation rights with option rights (disclosed in the "Notice of the conclusion of a memorandum of understanding to amend the contract regarding preferred negotiation rights with Daiichi Sankyo Co., Ltd. with option rights" on November 28, 2022) have also expired.

There is currently no particular impact on the full-year financial results for the fiscal year ending March 2026.

End.